Wesana Health May Sell Clinics to Focus Solely on Drug Development: An Analysis
Business, NewsWesana Health reaches a major strategic pivot point. Our resident Psychedelic Investor examines what this means for the company and industry at large.
Compass Pathways Shares ‘Promising’ Data That Psilocybin May Treat Anorexia
Business, ResearchThere is currently no FDA-approved treatment for anorexia. Could psychedelics be the answer?
Interview With Daniel Carcillo, Natalie Ginsberg, Olivia Mannix & Klee Irwin
Interviews, PodcastsThis week on the Psychedelic Spotlight podcast, we provide a recap of the inaugural Benzinga Psychedelic Capital Conference which took place in Fontainebleau Miami Beach on April 19, 2022.
Elon Musk Excites Psychedelic Industry CEOs with This Tweet
Business, NewsThis is one of the billionaire's most explicit acknowledgments of the power of psychedelics for mental health applications.
Kevin O’Leary Thinks MindMed, Compass Pathways & atai Will Merge | Is this a Good Idea?
VideosGet your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Join our Newsletter (scroll to the bottom of the page and sign up):
https://psychedelicspotlight.com/
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
Back to the potential MindMed, Compass Pathways & atai merger that Kevin O
Leary speculates on...
Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?
The "Shark Tank" star predicts three of the biggest psychedelic companies will merge into a mega-corporation, but our resident Psychedelic Investor wonders: Should they?
Famed investor Kevin O’Leary made a bold prediction last Tuesday, saying that psychedelic companies MindMed, atai Life Sciences and Compass Pathways will merge. For psychedelic stock investors, this would be a tsunami-sized event that would have ripple effects throughout the industry.
The Shark Tank star made the comments at the inaugural Benzinga Psychedelics Capital Conference in Miami, arguing that the companies “each need another $200 million by the time they get this to medicine.” In other words, as I have written before, the psychedelic medicines industry is heavily capital intensive, and getting multiple drugs from pre-clinical trials through Phase 3 trials and approved by the FDA can cost hundreds of millions of dollars.
Even though these companies are three of the best-financed in the industry — atai (Nasdaq: atai) has $362 million, Compass (Nasdaq: CMPS) has $273 million and MindMed (Nasdaq: MNMD, NEO: MMED) has $133 million — the celebrity investor believes that in order to succeed the companies may have to become one.
Read the entire article here: https://psychedelicspotlight.com/kevin-oleary-predicts-3-biggest-psychedelic-companies-will-merge-atai-mindmed-compass-pathways/
One man claims magic mushrooms healed his lost sense of smell. Read the full story here.
https://whyy.org/segments/could-magic-mushrooms-cure-covid-related-smell-loss/
A new anti-depressant study is out. Read the full study here: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0265928#sec011
#Mindmed #kevinoleary #psychedelicstocks
Why Field Trip Health Is Dividing in Two — and What This Means for Investors
Business, NewsField Trip Health plans to split into two independent, publicly traded companies: Field Trip Health and Wellness and Reunion Neuroscience.
Psychedelic Business Spotlight – April 29
Business, Stock ReportsThis week in psychedelic business news: Field Trip Health splits in two, Tryp Therapeutics commences study, and Optimi Health celebrates new facility.
Understanding 3 Risks of Investing in Psychedelic Stocks
Business, EditorialNo one is responsible for your financial future, other than yourself, so be responsible with your money.
Psychedelic Business Spotlight – April 22
Business, Stock ReportsThis week in psychedelic business news: Mindset Pharma files a new patent; Ehave's MetaHealthU app seeks to cure HPPD; Wellbeing Digital Sciences contemplates a sale.
Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?
Business, NewsOur resident Psychedelic Investor James Hallifax wonders if the "Shark Tank" star's prediction makes financial sense.